Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Alliances entities : Gilead sciences, inc. save search
Cognizant and Gilead Extend Partnership with Five-Year Service Agreement Estimated at $800 Million
Published: 2023-07-24 (Crawled : 17:00) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -1.02%
H: 0.45%
C: -2.71%
CTSH | $67.4 0.4% 0.4% 4.9M
|
Technology Services
|
| O: 0.13%
H: 1.38%
C: 0.82%
partnership service cognizant agreement
Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA
Published: 2023-06-01 (Crawled : 13:20) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: -1.72%
pipeline cell growing therapy
Pionyr Immunotherapeutics and Gilead Change Exclusive Option Agreement
Published: 2023-03-23 (Crawled : 11:00) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.04%
H: 1.48%
C: 1.26%
change agreement
Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
Published: 2023-01-30 (Crawled : 15:20) - biospace.com/
ACLX | $51.67 -5.19% -5.48% 740K
|
|
| O: -0.09%
H: 3.69%
C: -3.16%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.25%
H: 0.38%
C: -0.2%
agreement
Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
Published: 2022-12-09 (Crawled : 16:00) - biospace.com/
ACLX | $51.67 -5.19% -5.48% 740K
|
|
| O: 20.66%
H: 9.21%
C: 7.11%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -1.45%
collaboration
Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma
Published: 2022-12-09 (Crawled : 14:00) - biospace.com/
ACLX | $51.67 -5.19% -5.48% 740K
|
|
| O: 20.66%
H: 9.21%
C: 7.11%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -1.45%
collaboration
ImmunoGen Announces Clinical Collaboration with Gilead to Evaluate Pivekimab Sunirine in Combination with Magrolimab in Relapsed/Refractory Acute Myeloid Leukemia
Published: 2022-12-09 (Crawled : 13:00) - biospace.com/
IMGN | $31.23 0.03% 49M
|
Health Technology
|
| O: -0.19%
H: 0.77%
C: -0.77%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -1.45%
collaboration leukemia acute myeloid leukemia
Kite and Daiichi Sankyo Announce Changes to YESCARTA® CAR T-Cell Therapy Licensing Agreement in Japan
Published: 2022-12-07 (Crawled : 22:00) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.08%
H: 0.59%
C: -0.27%
yescarta japan t-cell agreement therapy
Jounce Therapeutics earns clinical milestone payment under the CCR8 exclusive license agreement with Gilead Sciences, Inc.
Published: 2022-11-02 (Crawled : 17:00) - biospace.com/
JNCE | $1.88 -2.59% -1.85% 0
|
Health Technology
|
| O: 0.46%
H: 0.0%
C: 0.0%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -1.46%
H: 2.33%
C: -0.38%
license therapeutics payment agreement milestone
Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers
Published: 2022-10-20 (Crawled : 14:20) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.05%
H: 0.57%
C: 0.0%
blood license agreement platform cancer
Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies
Published: 2022-10-17 (Crawled : 12:00) - biospace.com/
MGNX | $15.62 -2.8% -2.88% 1M
|
Health Technology
|
| O: 7.67%
H: 10.82%
C: 4.49%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 1.01%
H: 0.13%
C: -0.69%
collaboration
Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines
Published: 2022-09-22 (Crawled : 13:00) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.24%
H: 1.52%
C: 0.66%
hepatitis management
Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care
Published: 2022-08-17 (Crawled : 17:00) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.54%
H: 1.4%
C: 0.08%
care sciences collaboration hiv
Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury® (Remdesivir)
Published: 2022-07-19 (Crawled : 13:20) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 1.24%
H: 1.0%
C: 0.75%
veklury sciences agreement
Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation
Published: 2022-05-02 (Crawled : 14:00) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.35%
H: 1.47%
C: 1.28%
research collaboration
Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With KEYTRUDA® in First-Line Metastatic Non-Small Cell Lung Cancer
Published: 2022-01-10 (Crawled : 14:30) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 1.02%
H: 0.36%
C: 0.14%
keytruda
Everest Medicines Will Participate in a Clinical Trial with Gilead and MSD to Evaluate Trodelvy® in Combination with KEYTRUDA® (pembrolizumab) in First-Line Metastatic Non-Small Cell Lung Cancer
Published: 2022-01-10 (Crawled : 14:30) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 1.02%
H: 0.36%
C: 0.14%
keytruda
Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for Cancer
Published: 2021-08-05 (Crawled : 13:00) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.0%
H: 0.13%
C: 0.09%
collaboration cancer research announces collaboration therapy
Gilead and Novo Nordisk Expand NASH Clinical Collaboration
Published: 2021-03-18 (Crawled : 12:00) - biospace.com/
NVO | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -1.43%
H: 0.99%
C: 0.23%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -1.24%
H: 2.14%
C: 0.72%
collaboration nash expansion
Merck to Host Investor Briefing to Discuss Broad HIV Development Program and Newly Announced Collaboration with Gilead
Published: 2021-03-15 (Crawled : 12:00) - biospace.com/
MRK | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 1.21%
H: 1.4%
C: 0.97%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 1.28%
H: 1.32%
C: 1.15%
collaboration hiv announces collaboration
Gainers vs Losers
| 69% | 31% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
KNW 4 | $0.59 -0.71% 18.64% 27K
|
Manufacturing
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.